Eastgate Biotech Corp. (ETBI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | - | - | 0 | - |
| Operating profit | $m | -4 | |||||||
| Net profit | $m | - | - | - | - | - | - | -4 | - |
| EPS reported | $ | -0.01 | |||||||
| Operating cashflow per share | $ | 0.00 | |||||||
| Capex per share | $ | 0.00 | |||||||
| FCF per share | $ | 0.00 | |||||||
| Free cash flow | $m | -2 | |||||||
| Net debt | $m | 3 | |||||||
| Book value equity | $m | -5 | |||||||
| Book value per share | $ | -0.00 | |||||||
| Number of shares | m | 1,111.74 | |||||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | -0.59 | |||||||
| P/S LTM | x | 61.89 | |||||||
| P/FCF LTM | x | 102.56 | |||||||
| EV/EBITDA LTM | x | -3.44 | |||||||
| EV/Sales LTM | x | 106.96 | |||||||
| Earnings Yield LTM | % | -62.02% | |||||||
| FCF Yield | % | -28.37% | |||||||
| Quality | |||||||||
| ROE | % | +40.71% | |||||||
| ROIC | % | +63.23% | |||||||
| Operating margin | % | -32.82% | |||||||
| Gross margin | % | -1.10% | |||||||
| FCF/Sales | % | +60.34% | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | 0.00% | |||||||
| FCF/Debt | x | -0.57 | |||||||
| Net Debt/EBITDA | x | -1.45 | |||||||
| EBIT/Net interest | x | -12.10 | |||||||
| Net debt/market cap | % | +72.98% | |||||||
| Net debt/Equity | x | -0.51 | |||||||
| Gross debt/equity | x | -0.58 | |||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body. The firm employs cutting-edge nanotechnologies to provide healthier options compared to conventional pharmaceuticals, which often lead to detrimental side effects and unforeseen issues for individuals seeking to achieve and maintain good health. Among its diverse product line are E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X. EastGate Biotech's development process involves integrating product components into various nano-sized delivery systems. These systems include oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations of polymers, lipids, and surfactants (such as hybrid nanoparticles, nanocapsules, and mixed micelles). The company has operational bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
EastGate Biotech Corp. is a pharmaceutical company specializing in the production and distribution of nutraceuticals. These products are rooted in natural therapies and designed for natural absorption within the body. The firm employs cutting-edge nanotechnologies to provide healthier options compared to conventional pharmaceuticals, which often lead to detrimental side effects and unforeseen issues for individuals seeking to achieve and maintain good health. Among its diverse product line are E-Drops NANO, Essential D, GluCora, VCleanzz, Cleanezze, and Warts X. EastGate Biotech's development process involves integrating product components into various nano-sized delivery systems. These systems include oil droplets (nanoemulsions), polymeric particles (nanoparticles), and complex combinations of polymers, lipids, and surfactants (such as hybrid nanoparticles, nanocapsules, and mixed micelles). The company has operational bases in prominent cities including New York, London SF, Cockfosters BP, Los Angeles, Chicago, and Las Vegas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free